Warren Lowman

Dr. Warren Lowman

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2016 in World Journal of Emergency Surgery
Verified
Journal Article
Open access
PDF file
Massimo SartelliMassimo Sartelli
Massimo Sartelli
DWDieter G. Weber
Dieter G. Weber
ERETIENNE RUPPE
ETIENNE RUPPE
MBMatteo Bassetti
Matteo Bassetti
BWBrian J. Wright
Brian J. Wright
PVPerluigi Viale
Perluigi Viale
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients. The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy. Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance. The overuse of antimicrobials is widely accepted as a major driver of some emerging infections (such as C. difficile), the selection of resistant pathogens in individual patients, and for the continued development of antimicrobial resistance globally. The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria. An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials for patients with IAIs. The project has been termed AGORA (Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections). The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.

1 December 2010 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
WLWarren Lowman
Warren Lowman
NANaseema Aithma
Naseema Aithma
Nocardiosis is an underrecognized clinical entity in South Africa, for which interspecies epidemiological and clinical differences are poorly understood. The taxonomical state of flux and the lack of a simple antimicrobial susceptibility testing method are partly responsible. Definitive identification is molecularly based, which further complicates the study of this ubiquitous organism, as this methodology is beyond the scope of most routine diagnostic laboratories. The Etest methodology has been proposed as an alternative to the reference broth microdilution method, although there have been a limited number of comparative studies. We profiled 51 clinical isolates of aerobic actinomycetes, including 39 Nocardia species, using sequence-based (16S rRNA) identification. Broth microdilution and Etests were done concurrently on all isolates. The overall level of categorical and essential agreement for broth microdilution and Etest for the Nocardia isolates ranged from 67.5 to 100% and 46.2 to 81.6%, respectively. Very major errors were seen with amikacin, amoxicillin-clavulanate, ciprofloxacin, clarithromycin, and imipenem. For Nocardia species, uniform susceptibility to co-trimoxazole, amikacin, and linezolid was demonstrated, with a 48.8% susceptibility rate to imipenem. Nocardia farcinica (20.5%) and Nocardia cyriacigeorgica (15.4%) were the most commonly identified species among the 82% of isolates identified to species level using 16S rRNA sequences. Furthermore, drug susceptibility patterns demonstrated limited concordance with species identification. Our results suggest that, in a routine diagnostic setting, the Etest is not an acceptable alternative to the reference method of broth microdilution for antimicrobial susceptibility testing. Given the diversity and limited understanding of this group of organisms, further widespread evaluation of clinical isolates, from both clinical and diagnostic perspectives, is warranted.

7 April 2016 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
WLWarren Lowman
Warren Lowman
Active surveillance of hospital-acquired infections in South Africa: Implementation, impact and challenges

26 September 2019 in Southern African Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NGNelesh P. Govender
Nelesh P. Govender
TATheunis Avenant
Theunis Avenant
Adrian John MBCHB, MMedAdrian John MBCHB, MMed
Adrian John MBCHB, MMed
VCVindana Chibabhai
Vindana Chibabhai
JCJoy Cleghorn
Joy Cleghorn
ESErika van Schalkwyk
Erika van Schalkwyk
Candida auris has been detected at almost 100 South African hospitals, causing large outbreaks in some facilities, and this pathogen now accounts for approximately 1 in 10 cases of candidaemia. The objective of this guideline is to provide updated, evidence-informed recommendations outlining a best-practice approach to prevent, diagnose and manage C. auris disease in public- and private-sector healthcare settings in South Africa. The 18 practical recommendations cover five focus areas: laboratory identification and antifungal susceptibility testing, surveillance and outbreak response, infection prevention and control, clinical management and antifungal stewardship.

19 February 2013 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
WLWarren Lowman
Warren Lowman
LVLaurissa Venter
Laurissa Venter
JSJuan Scribante
Juan Scribante
Bacterial contamination of re-usable laryngoscope blades during the course of daily anaesthetic practice

20 October 2022 in Southern African Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
Adrian John MBCHB, MMedAdrian John MBCHB, MMed
Adrian John MBCHB, MMed
JCJennifer Coetzee
Jennifer Coetzee
GRGuy Richards
Guy Richards
CFCharles Feldman
Charles Feldman
WLWarren Lowman
Warren Lowman
MMMarc Mendelson
Marc Mendelson
Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidime-avibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa’s multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term.